The accuracy of polygenic score models for anthropometric traits and Type II 1 2 **Diabetes in the Native Hawaiian Population**

3 Ying-Chu Lo¹, Tsz Fung Chan¹, Soyoung Jeon¹, Gertraud Maskarinec², Kekoa Taparra³, Nathan Nakatsuka⁴, Mingrui Yu^{5,6}, Chia-Yen Chen^{5,6,7,8}, Yen-Feng Lin^{6,9,10}, Lynne R. Wilkens², Loic Le 4 Marchand², Christopher A. Haiman^{1,11}, and Charleston W.K. Chiang^{1,11,12} 5

6

7 ¹Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of

8 Medicine, University of Southern California, Los Angeles, CA, USA.

9 ²Epidemiology Program, University of Hawai'i Cancer Center, University of Hawai'i, Manoa, Honolulu, 10 HI, USA.

- 11 ³Standard Health Care, Department of Radiation Oncology, Palo Alto, CA, USA.
- 12 ⁴New York Genome Center, New York, NY, USA.
- 13 ⁵Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 14 ⁶Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan
- 15 ⁷Biogen, Cambridge, MA, USA
- 16 ⁸Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 17 ⁹Department of Public Health & Medical Humanities, School of Medicine, National Yang Ming Chiao 18 Tung University, Taipei, Taiwan
- 19 ¹⁰Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- 20 ¹¹Cancer Epidemiology Program, Norris Comprehensive Cancer Center, University of Southern California,
- 21 Los Angeles, CA, USA.
- 22 ¹²Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, 23 CA, USA.
- 24

25 Abstract

- 26 Polygenic scores (PGS) are promising in stratifying individuals based on the genetic susceptibility
- 27 to complex diseases or traits. However, the accuracy of PGS models, typically trained in European-
- 28 or East Asian-ancestry populations, tend to perform poorly in other ethnic minority populations,
- 29 and their accuracies have not been evaluated for Native Hawaiians. Using body mass index, height,
- 30 and type-2 diabetes as examples of highly polygenic traits, we evaluated the prediction accuracies
- of PGS models in a large Native Hawaiian sample from the Multiethnic Cohort with up to 5,300 31
- 32 individuals. We evaluated both publicly available PGS models or genome-wide PGS models
- 33 trained in this study using the largest available GWAS. We found evidence of lowered prediction
- 34 accuracies for the PGS models in some cases, particularly for height. We also found that using the
- Native Hawaiian samples as an optimization cohort during training did not consistently improve 35 PGS performance. Moreover, even the best performing PGS models among Native Hawaiians 36
- 37 would have lowered prediction accuracy among the subset of individuals most enriched with
- 38 Polynesian ancestry. Our findings indicate that factors such as admixture histories, sample size
- 39
- and diversity in GWAS can influence PGS performance for complex traits among Native Hawaiian 40 samples. This study provides an initial survey of PGS performance among Native Hawaiians and
- 41 exposes the current gaps and challenges associated with improving polygenic prediction models
- for underrepresented minority populations.
- 42 43
- 44 Keywords: Native Hawaiians, Polygenic Scores, GWAS summary statistics, BMI, height, type-2
- 45 diabetes
- 46

It is made available under a CC-BY-NC-ND 4.0 International license .

47 Introduction

48 Genome-wide association studies (GWAS) have identified thousands of genetic variants 49 associated with a plethora of human complex traits and diseases [1,2]. The success of GWAS has 50 enabled a burgeoning field of post-GWAS analysis, including the computation of polygenic scores 51 (PGS) for predicting the genetic risk for an individual based on their genotypes and available 52 GWAS summary statistics to common diseases or complex traits [3,4]. On the basis of the GWAS 53 summary statistics, the PGS is calculated as the sum of the trait-associated alleles an individual 54 carries, weighted by the estimated effect sizes of the alleles. Recent developments have focused 55 on extending PGS modeling to include variants and their appropriate weights genome-wide. Such 56 genome-wide PGS tend to be more efficacious in predicting outcome than a simple approach of 57 selecting only genome-wide significantly associated variants [5–7].

58 As the sample sizes of GWAS increased, the resulting PGS has become more effective in risk 59 predictions, early disease detection, and the development of precision medicine [8,9]. However, 60 available GWAS data are heavily biased towards European-ancestry individuals [10,11], posing a challenge for PGS due to its poor transferability between populations. In particular, PGS trained 61 62 with European populations exhibit reduced prediction accuracy when applied to non-European 63 populations [12,13]. This poor transferability has been demonstrated for several ethnic minority 64 populations but has not been evaluated for Native Hawaiians, who make up the largest Pacific 65 Islander population in the U.S. [14].

Native Hawaiians are known to have a higher risk of obesity, diabetes, and cardiovascular 66 67 disease, among others both within Hawai'i and nationally [15–19]. They also have the highest 68 mortality rate in several types of cancer compared to other ethnic groups [20-22]. In addition, as 69 consequence of centuries of colonization and globalization, Native Hawaiians are largely 70 admixed[23-25], representing ancestry components derived from Polynesian ancestors (~40%) 71 and recent (within the last 300 years or so) admixtures from European (~30%) and East Asian 72 (~29%) immigrants, among others. These ancestries can also be correlated with elevated risks of 73 certain metabolic diseases [15–17,19]. Despite these elevated disease risks, the Native Hawaiian 74 population is largely understudied and underserved [23,25]. We generally lack the genomic 75 resources and knowledge for this population to reap the benefits of genetic research and genomic 76 medicine [23,26].

77 Predictions based on PGS is one area that is under-investigated for Native Hawaiians and can 78 be potentially improved. To date, no systematic evaluation of PGS, particularly for metabolic traits 79 and diseases such as body mass index (BMI) and type 2 diabetes (T2D), have been conducted for 80 the Native Hawaiians. Given the underrepresentation of Polynesian ancestries in genomic studies 81 and references, poor transferability of PGS models trained in the largest GWAS dataset is expected 82 as is often observed with other populations and ethnic minorities. On the other hand, it is unclear 83 whether the admixture alleviates some of the transferability issues of PGS at the population level. 84 Because admixture levels vary across individuals within a population, even if admixture alleviates 85 some of the transferability issues, it could create disparity within Native Hawaiian communities depending on individual's genomic similarity to the underrepresented Polynesian ancestries. It is 86 87 thus crucial to evaluate the transferability of PGS in this population and assess any disparities 88 specific to Native Hawaiians in order to begin bridging this gap.

We conducted the present study using data from the Multiethnic Cohort (MEC) [27]. We leveraged the data of approximately 5,300 Native Hawaiian (MEC-NH), as well as populations as proxies for East Asian- and European ancestries (approximately 19,600 Japanese Americans, MEC-J; approximately 8,500 White Americans, MEC-W), who were genotyped on the Multi-

93 Ethnic Global Array (MEGA) or Global Diversity Array (GDA) arrays to evaluate the prediction 94 accuracy of PGS for BMI, height, and T2D. We trained PGS models using summary statistics from 95 the largest available consortium GWAS from European (EUR), East Asian (EAS), or multi-ethnic 96 populations for BMI, height, and T2D. We focused on these traits as they are the most available 97 and because they are closely linked to obesity, diabetes, and cardiovascular disease – diseases that 98 show elevated risks within the Native Hawaiian population [18,28,29]. Furthermore, T2D was 99 identified as one of the diseases that the Native Hawaiian communities expressed the most 100 concerns [17,30]. Additionally, we assessed the efficacies of published PGS models from the PGS 101 catalog [31] in MEC-NH. In each case, we also investigated the model efficacy in subsets of Native 102 Hawaiians with higher estimated Polynesian ancestry.

103 We stress that we utilized this study design as a way to examine health disparities within the 104 Native Hawaiian population, and as a way to evaluate how these models may transfer to other 105 Polynesian-ancestry populations. We used empirical (and potentially noisy) estimates of genetic 106 ancestries as a means to assess the impact on the accuracy of currently available PGS models due 107 to admixture over the last 10-12 generations, which is a product of the colonization of the Hawaiian 108 archipelago by Western countries. Interpretations of these estimates beyond the research context 109 are socially complex, and thus should not supplant current practices based on genealogical records 110 and self-reports. These estimates also do not imply any hierarchies or socially meaningful 111 subdivisions in the Native Hawaiian communities.

112

113 **Results**


114

115 **Overview of the study design**

116 Focusing on complex traits and diseases (*i.e.* BMI, height, and T2D) for which large-scale 117 GWAS summary statistics are publicly available, we took two different approaches to construct 118 PGS models for evaluation (Fig. 1). We collected from literature the largest East Asian-ancestry 119 (EAS), European-ancestry (EUR), and multi-ancestry (META) meta-analysis GWAS summary 120 statistics for each trait (Table S1) to train PGS models. Based on the summary statistics for a 121 particular trait, we used independent MEC subcohorts for as reference for linkage disequilibrium 122 (LD) (N = 500) and for PGS optimization (N = 3000), and then validated the PGS model in an 123 additional held-out sample (N = 1000) (Methods). We trained and optimized PGS models in either 124 EUR-, EAS- or multi-ancestry cohorts, and tested the transferability of the best performing 125 genomic PGS models in Native Hawaiians (Design I in Fig. 1).

126 Secondly, we explored the potential of using Native Hawaiians as the optimization cohort to 127 improve the accuracies of PGS models within MEC-NH (Design II in Fig. 1). Because the Native 128 Hawaiian population, or even the larger Polynesian-ancestry Pacific Islander populations, are 129 generally much smaller in sample sizes compared to the available consortium GWAS from 130 continental populations, it is generally infeasible to amass the sample sizes necessary for a well-131 powered GWAS that will be informative for PGS construction. We thus investigated whether the 132 MEC-NH could be used for identifying the optimal PGS model to improve upon on the accuracy 133 (hence alleviate the transferability issues) of PGS, even though the GWAS summary statistics were 134 still derived from EAS, EUR, or multi-ancestry meta-analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .



137 Fig 1. The overall study design of PGS evaluation in Native Hawaiians. The GWAS summary statistics were 138 downloaded from large consortiums and biobanks (BBJ, UKB+GIANT, BBJ+TWB, and META). Each population-139 specific GWAS (EAS, EUR) were used to train PGS models with the matching MEC cohort as the LD reference and 140 optimization cohort (MEC-J for EAS, MEC-W for EUR). Multi-ancestry meta-analysis GWAS (META) were used 141 to train PGS for both EAS and EUR populations. In Design I, EAS- or EUR-optimized PGS were validated in held-142 out MEC-J, MEC-W and MEC-NH samples. Comparisons of PGS prediction accuracy between MEC-NH and MEC-J or MEC-W provide the metric for transferability. In Design II, PGS models based on EAS or EUR GWAS were 143 144 using MEC-NH, and the performance in held-out MEC-NH were then compared to the corresponding metric in Design 145 I to assess potential improvement of prediction by PGS for MEC-NH. See Table S1 for detailed descriptions of the 146 GWAS datasets used for this study. 147

It is made available under a CC-BY-NC-ND 4.0 International license .

Reduced prediction accuracy when applying EAS- or EUR-trained PGS to Native Hawaiians in some scenarios


150 We first assessed the transferability of PGS to the Native Hawaiian population (Design I in 151 Fig. 1). In this case, we identified GWAS summary statistics to build and optimize the PGS model 152 using population-matched cohorts from the MEC, with the Japanese and Whites as representatives 153 of the East Asian and European-ancestry cohorts, respectively (i.e. EAS GWAS were optimized 154 using MEC-J; EUR GWAS were optimized using MEC-W; Multi-ancestry GWAS were optimized 155 using either MEC-J or MEC-W separately). We then evaluated the performance of the PGS in 156 held-out MEC-J, MEC-W, and MEC-NH individuals by R². Poor transferability is indicated if 157 there is a noticeable drop-off in prediction accuracy when a PGS model optimized in one 158 population (e.g. EAS GWAS optimized in MEC-J) is tested in another population (e.g. MEC-W 159 or MEC-NH validation cohort).

160 As expected, PGS models optimized in MEC-J or MEC-W showed the highest prediction 161 accuracy in validation cohorts from the same populations (Fig. 2). For instance, for BMI based on 162 GWAS summary statistics from BBJ, the best PGS model optimized in MEC-J achieved the 163 highest partial R^2 in held-out MEC-J samples among the validation cohorts tested (partial R^2 = 164 0.059), while the best PGS model based on GWAS summary statistics from GIANT+UKB and 165 optimized in MEC-W achieved the highest partial R^2 in held-out MEC-W (partial $R^2 = 0.088$). 166 Moreover, consistent with the expectation of poor transferability, PGS trained in EAS tend to have 167 reduced prediction accuracy in the other continental population. For instance, for BMI, EAS-168 trained PGS model for BMI had reduced partial R^2 in MEC-W (0.059 vs. 0.022; one-sided p =169 0.041 by bootstrapping), and EUR-trained PGS model for BMI performed more poorly in MEC-J 170 (0.088 vs. 0.043; one-sided p = 0.045). PGS models trained from multi-ancestry meta-analysis 171 GWAS sometimes reduced the gap in prediction accuracy between MEC-J and MEC-W, though 172 they do not necessarily have higher population-specific prediction accuracies depending on the 173 traits examined (Fig. 2).

174 When validating EAS- or EUR-trained PGS in the Native Hawaiian cohort, transferability 175 was not consistently poor, depending on the trait or the GWAS summary statistics used for training 176 (**Fig.2**). For height, there were noticeable reduction in prediction accuracy (*e.g.* for EAS-trained 177 PGS based on the BBJ GWAS, partial $R^2 = 0.253$ in MEC-J to 0.048 for MEC-NH; one-sided 178 p<0.001). In contrast, EAS- or EUR-trained PGS for BMI showed little drop-off when evaluated 179 in MEC-NH (**Fig.2**). T2D PGS models showed similar pattern as BMI, though the overall 180 prediction accuracy (*e.g.* for EAS-trained PGS)

180 prediction accuracies are relatively low (Fig.2)

It is made available under a CC-BY-NC-ND 4.0 International license .




181 182 Fig 2. The transferability of EAS- and EUR-trained PGS for BMI, height and T2D. The genomic PGS model 183 with the highest prediction accuracy in optimization cohorts was validated in held-out MEC-J. MEC-W, and MEC-184 NH cohorts. This figure summarizes the results of analysis in Design I, Fig.1, and details of the model parameter for 185 the best performing PGS model can be found in **Table 1**. Best model based on the C+T or LDpred2 approach are 186 represented by blank or hashed bars, respectively. The standard error for the R² were calculated using 1,000 sets of 187 bootstrap samples. For BMI and height, random 1,000 individuals from each of MEC-J, MEC-W, and MEC-NH were 188 used for validation. For T2D, all cases and controls that were not used in training were used for validation: 3,315 cases 189 and 6,700 controls for MEC-J, 496 cases and 4,063 controls for MEC-W, 392 cases and 549 controls for MEC-NH. 190

191 PGS optimized in Native Hawaiians did not necessarily improve the PGS transferability

192 In absence of a large-scale powerful GWAS in Polynesian-ancestry populations, another 193 possibility to improve the PGS prediction accuracies for Native Hawaiians may be to use the MEC-194 NH cohort for optimization, as this may lessen the differences in linkage disequilibrium between the training and validating cohorts and thereby reduce the transferability gap of PGS. Therefore, 195 196 we employed MEC-NH as an additional optimized cohort, following the same pipeline (Design II, 197 Fig.1) to compare with the PGS models optimized using MEC-J and MEC-W. When validated in 198 held-out MEC-NH samples, we observed that generally speaking, PGS models optimized in MEC-199 NH did not necessarily have better prediction accuracy in the validation cohort (Fig.3). NH-200 optimized PGS models have at best similar prediction accuracies, if not worse (Fig. 3). Our results 201 thus suggest that optimization in MEC-NH did not necessarily lead to improved PGS accuracy 202 compared to using the optimization cohort with consistent ancestry as the cohort generated the 203 GWAS summary statistics.

It is made available under a CC-BY-NC-ND 4.0 International license .



205 206 Fig 3. The impact of MEC-NH as optimization cohort on PGS prediction accuracies in held-out MEC-NH for 207 BMI, height, and T2D. For each combination of GWAS-trait PGS models that was previously optimized in MEC-J 208 or MEC-W in Fig.2, the same data was then optimized using MEC-NH samples here (Design II, Fig.1). Previously 209 optimized PGS models and the MEC-NH-optimized models were both validated in the held-out MEC-NH cohort to 210 evaluate if optimization in MEC-NH would improve the prediction accuracy in Native Hawaiians. Details of the model 211 parameter for the best performing PGS model can be found in Table S2. Best model based on the C+T or LDpred2 212 approach are represented by blank or hashed bars, respectively. The standard error for the R^2 were calculated using 213 1,000 sets of bootstrap samples. For BMI and height, random 1,000 MEC-NH individuals were used for validation. 214 For T2D, 392 cases and 549 controls from MEC-NH were used for validation.

215


216 Prediction accuracy of publicly available PGS models for Native Hawaiians

We constructed the PGS evaluated here based on limited number of, albeit some of the largest and most recent, GWAS meta-analysis datasets for BMI, height, and T2D (**Table S1**). However, there are a number of published PGS models for these traits in the PGS catalog (**Table S2**, URL https://www.pgscatalog.org/), some of which may have used different GWAS datasets or different methodologies for constructing PGS. We thus validated all of the BMI (N = 11), height (N = 4), and T2D (N = 10) PGS models available as of mid-2022 in MEC-NH, and compared them with our top-performing PGS.

It is made available under a CC-BY-NC-ND 4.0 International license .

We found that the PGS developed in this study aligns closely with the best-performing public PGS models for BMI and height in terms of prediction accuracy (**Fig. 4**). Moreover, in the case of T2D, our PGS models developed based on the GWAS summary statistics from the DIAMANTE European- or multi-ancestry meta-analysis [32] showed a higher level of predictive accuracy than other PGS models found in the PGS catalog (**Fig.4**).

- 229
- 230
- 231



232 233

Fig 4. A Comparison of PGS between the optimal PGS from this study and PGS from the PGS-catalog. PGS models available on the PGS catalog (URL https://www.pgscatalog.org/) as of May 18, 2022 were downloaded for BMI, height, and T2D, and validated in the same MEC-NH individuals here. Blue bars represent the PGS constructed in this study with the highest prediction accuracy in MEC-NH. Clear and hash bars indicate the PGS was derived from C+T or LDPred2 approaches. Gray bars depict PGS from the PGS catalog. For BMI and height, random 1,000 MEC-NH individuals were used for validation. For T2D, 392 cases and 549 controls from MEC-NH were used for validation.

Reduced PGS prediction accuracy in the Native Hawaiians most enriched with Polynesian ancestries


242 The relatively comparable prediction accuracy of EAS- or EUR-trained PGS models or 243 publicly available PGS models in MEC-NH could be in part driven by admixture. However, 244 Polynesian ancestries exist on a continuum in the population. Because Polynesian ancestries are 245 likely the component of ancestries least similar to the ancestries of individuals participating in the 246 GWAS datasets, there may be disparity in PGS prediction accuracy among individuals with 247 different proportions of Polynesian ancestries [33]. Thus, we explored the accuracy of PGS in subsets of 1000 Native Hawaiians with highest Polynesian ancestries (PNS; minimum estimated 248 proportion of ancestry = 65%), and compared to the 1000 randomly selection individuals. For 249 some PGS models, particularly the best publicly available PGS models for BMI, there was 250 251 substantially reduced prediction accuracy within the PNS subsets (Fig.5). For instance, the partial 252 R^2 for model PGS00910 was 0.088 in randomly selection MEC-NH, but 0.040 when applied in

It is made available under a CC-BY-NC-ND 4.0 International license .


253 PNS (one-sided P = 0.04). In contrast, the PGS model in this study using the MEC-NH for 254 optimization showed relatively little reduction in performance (Fig. 6). These findings suggest that 255 while optimizing PGS in MEC-NH may not necessarily lead to improved transferability across 256 Native Hawaiians in general, it could yield enhanced PGS accuracy among Native Hawaiians 257 enriched with Polynesian ancestries, and thus may be more applicable to other Polynesian-ancestry 258 populations across the Pacific. However, because most of the MEC-NH data were used for 259 optimizing the PGS model, we have fewer individuals enriched with Polynesian ancestry to use as 260 validation, resulting in larger error bars and less stable estimates of the prediction accuracy of the 261 PGS models, and preventing us from evaluating PGS models for T2D as we ended with insufficient 262 number of cases and controls.







265 266 Fig 5. Prediction accuracies of models from PGS catalog in the random Native Hawaiian and Native Hawaiian 267 with highest Polynesian ancestry validation sets. Each PGS model from PGS catalog was assessed in validation 268datasets from MEC-NH. For BMI and height, the validation cohort consisted of randomly selected 1000 MEC-NH or 269 the 1000 individuals with the highest estimated Polynesian ancestry (minimum estimated Polynesian ancestry = 65%) 270 among the entire MEC-NH cohort. This was not restricted to the 1,000 individuals reserved for validation in Figures 2712-4 as none of the MEC-NH individuals were used in construction of the publicly available PGS models. For T2D, 272 because only 768 individuals (346 cases, 422 controls) with > 65% estimated Polynesian ancestry were available, we 273 compared to 768 randomly selected MEC-NH individuals (318 cases, 450 controls).



274 275

276 Fig 6. Prediction accuracies of models from this study in the random Native Hawaiian and Native Hawaiian 277 with highest Polynesian ancestry validation sets. The PGS models were all trained from EAS-, EUR- or multi-278 ancestry GWAS, but using the MEC-NH for optimization. The resulting models were then validated in 200 randomly 279 selected MEC-NH individuals and the same number of individuals with highest estimated Polynesian ancestries 280 (minimum estimated Polynesian ancestry = 65%). We did not perform the analysis for T2D due to too few case / 281 control samples, particularly among those with high Polynesian ancestries. 282

283 Discussion

284 In this study we conducted a systematic assessment of the prediction accuracies and 285 transferability of PGS models for Native Hawaiians. We assessed either PGS models constructed 286 in this study or models that are publicly available from the PGS catalog. We focused on BMI, 287 height, and T2D, as these are traits or diseases that showed different distributions between Native 288 Hawaiians and other continental populations, and that Polynesian ancestries may be correlated 289 with disease risk [15]. While we observed that EAS-trained PGS models have reduced prediction 290 accuracy in MEC-W (the MEC cohort representing EUR ancestries) and vice versa, our results 291 revealed that these PGS models at times showed comparable prediction accuracies in the Native 292 Hawaiian cohort, especially for BMI and T2D. Empowered by the Native Hawaiian cohort in the 293 Multiethnic Cohort Study (N ~ 5,300 with genome-wide genotyping array data), we were also able 294 to evaluate whether using the MEC-NH individuals for optimizing the PGS model could improve 295 PGS prediction accuracies for this population, even though our findings suggested limited 296 improvements. Furthermore, because the Native Hawaiian population displays a continuum of 297 genetic ancestry due to its colonial history, with Polynesian ancestries being the majority ancestry, 298 we also evaluated PGS prediction accuracies as function of this ancestry. For publicly available 299 PGS models for BMI and T2D, we did observe a reduction in prediction accuracy when applied to 300 the Native Hawaiians most enriched with Polynesian ancestries. Our results suggest that recent 301 admixture with European or East Asian ancestries are mediating the PGS performance, and these 302 PGS models in general may be even less applicable to the Polynesian-ancestry populations across 303 the Pacifics at large.

304 Across the traits, populations, and GWAS datasets that we examined here for training PGS 305 models for Native Hawaiians, irrespective of the degree of reduction in prediction accuracy, we

It is made available under a CC-BY-NC-ND 4.0 International license .

found that training with European-based GWAS generally produced better performing PGS 306 models. For instance, the prediction accuracy by partial R² of height PGS model from the 307 308 UKB+GIANT dataset (N = \sim 700,000), optimized in MEC-W, was 0.198 in validation MEC-NH, 309 compared to 0.074 for PGS model derived from BBJ+TWB GWAS data (N = 102,900) with 310 optimization in MEC-J (one-sided P < 0.001; Fig.2). This is thus reflective of the bias in GWAS, 311 where ancestry-specific GWAS for European-ancestry populations are still much larger, and thus 312 more powered and informative for PGS, than East Asian-ancestry populations. Another hint of this 313 bias can also be observed when PGS was constructed from multi-ancestry meta-analysis data. In 314 this case, the same GWAS dataset was optimized in MEC-W or MEC-J separately, but the 315 resulting PGS still had higher prediction accuracy in held-out MEC-W (partial $R^2 = 0.286$) than 316 MEC-J (0.199; one-sided P = 0.023), respectively. This is potentially due to the European-ancestry 317 populations still representing the majority of the dataset in the multi-ancestry meta-analysis 318 (~628,000 European-ancestry individuals vs. ~ 179,000 East Asian-ancestry individuals in Sakaue 319 S., et al. [34]). Therefore, in addition to increasing sample sizes of future GWAS, increasing 320 representation and diversity of these GWAS will also help improve the PGS accuracy, particularly 321 for a population such as the Native Hawaiians (or African Americans and Latinos) who are not a 322 major constituent of multi-ancestry GWAS yet. This may be particularly important since using the 323 diverse population for optimization, without fundamentally changing the representation of the 324 GWAS data, did not appear to make meaningful improvements (Fig.3).

325 While we generally advocate for greater inclusion of diverse populations in future GWAS, 326 which both increase the sample size and the diversity of the GWAS, it could also be difficult to 327 predict the impact on prediction accuracy of the PGS and may be dependent on the trait architecture. 328 For instance, the same multi-ancestry meta-analysis cohort optimized in MEC-W individuals 329 showed an improvement in prediction accuracy for BMI (partial $R^2 = 0.104$, compared to partial 330 $R^2 = 0.088$ in UKB+GIANT only; P < 0.001 by paired bootstrapping; Fig.2), but a reduction for 331 height (partial $R^2 = 0.286$ in multi-ancestry meta-analysis, compared to $R^2 = 0.328$ in 332 UKB+GIANT; P < 0.001; Fig.2). For Native Hawaiians, switching from a smaller European-only 333 GWAS to a marginally larger multi-ancestry GWAS did not improve the prediction accuracies for 334 either trait, though the performance was comparable (partial $R^2 = 0.081$ vs. 0.078 for BMI, 0.198 335 vs. 0.176 for height; Fig. 2). It is therefore important to assess the prediction accuracy empirically, 336 particularly for the diverse ethnic minority populations such as the Native Hawaiians.

337 In addition to sample size and diversity of the GWAS dataset for training, the size of the 338 optimization and validation samples may also play a role in determining the transferability of the 339 resulting PGS model. In particular, we had compared the PGS models constructed here with those 340 publicly available on the PGS catalog (Fig. 4). For some traits, our models may have used larger 341 GWAS but achieved only comparable, if not lower, prediction accuracies compared to the 342 published PGS models. For instance, in the case of height PGS, PGS001929 [35] showed 343 significantly better performance than our best model (partial R2 = 0.236 vs. 0.198; P = 0.02; 344 Fig.4). PGS001929 utilizes only the UKB GWAS (N ~500,000) and employs the same LDpred2 345 for PGS construction. The improved performance in PGS001929 may be attributed to a larger 346 optimized dataset and validation sample sizes (N = 349,991 and 43,631, respectively). Our 347 observations here then suggest that the most effective study design to construct PGS for 348 underrepresented admixed populations may be using the largest and most diverse GWAS along 349 with a large sample for optimization. This is yet another challenge for underrepresented minority 350 populations such as the Native Hawaiians when sample sizes are generally small.

It is made available under a CC-BY-NC-ND 4.0 International license .

351 In summary, our study informs on PGS performance and transferability in the Native 352 Hawaiians and individuals with Polynesian ancestry. We found that continental-level admixture, 353 over the last 300 years or so, may have mediated the PGS performance for these complex traits in 354 Native Hawaiians. We again stress that our use to quantify proportion of ancestries was solely for 355 the purpose of research use, as a means to evaluate potential disparity in the way PGS can be 356 deployed within the Native Hawaiian population. These estimates are potentially noisy, dependent 357 on external references used, and could induce social harm when taken out of the particular research 358 context. In fact, one future approach to evaluate PGS performance may focus on individual-level 359 metric, where one's genetic information is evaluated in context of genetic similarity to, say, the 360 European cohort underlying the GWAS study[33], rather than explicit quantification of proportion 361 from a labeled ancestry. We also found that sample size and diversity in GWAS, as well as the 362 availability of large optimization cohort, may complicate the construction and application of PGS 363 in underrepresented populations. This is another obstacle for Native Hawaiians, as collection and 364 use of genetic data from indigenous populations are fraught with past misuse that led to general 365 mistrust from the community [36-38]. For a population already small in size, the availability of 366 cohorts to optimize these PGS models are also much smaller than that available for other 367 continental populations, which in turn harms the community in reaping the benefits of genomic 368 medicine. Thus, an ongoing discussion, engagement, and involvement of the community centered 369 around issues of participation in research, genetic data collection, and data sovereignty will be 370 required. Finally, future studies may also focus on traits and diseases that we did not study here, 371 such as cardiovascular diseases that the Native Hawaiians are also known to be susceptible [18,39], 372 as well as traits that the Native Hawaiian communities expressed explicit concern and should be 373 made as research focus, such as asthma [17,30], so to further encourage community participation 374 in research. It is with the multi-pronged strategy of inclusion in genetics research, reduction of 375 biases, and focus on community concerns that we can reduce the disparity in PGS model 376 performance in this case, and alleviate health disparity in general.

377

378 Material and Methods

379 GWAS summary statistics and PGS Catalog datasets

380 To comprehensively evaluate the transferability of PGS for the Native Hawaiian population, 381 an admixed population with substantial East Asian (EAS) and European (EUR) ancestries [19], 382 we have utilized EAS and EUR GWAS, as well as multi-ethnic GWAS, summary statistics for training PGS models for BMI, height, and T2D. We collected and curated the largest available 383 384 GWAS summary statistics data from the most recent publications [32,34,40–43] (Table S1). In 385 addition to training PGS models from these latest GWAS, we also obtained and tested all models 386 from the PGS-catalog database (http://www.pgscatalog.org/) related to these three traits, published 387 in the database as of 05/18/2022 (Table S4).

In all cases, we downloaded the datasets in GRCh38 coordinates or converted the coordinates to GRCh38 genome build using triple LiftOver [44] to ensure alleles are aligned in genomic regions that may have inverted between genome builds. Additionally, we verified the order of reference and alternative alleles in the GWAS summary data by comparing it to the GRCh38 reference genome. We also removed the indels in the GWAS summary statistics data.

393

394 Study cohorts and quality controls of individual data

To optimize the PGS models for each trait, and to evaluate the prediction accuracy and transferability of each PGS model, we leveraged the individual genetic data from the Multiethnic

It is made available under a CC-BY-NC-ND 4.0 International license .

397 Cohort (MEC) study [27]. MEC encompasses five major ethnic groups: Japanese Americans, 398 Native Hawaiians, African Americans, Latinos, and Non-Latino Whites, with up to approximately 399 70,000 individuals with genome-wide array data. We utilized the subcohorts genotyped with the 400 Illumina Multi-Ethnic Global Array (MEGA) and Global Diversity Array (GDA) arrays, in total 401 containing 19,677 (MEGA: 5,022; GDA: 14,655) Japanese Americans (MEC-J), 11,316 (MEGA: 829; GDA: 10,487) Non-Latino White (MEC-W), and 5,388 (MEGA: 4,144; GDA: 1,244) Native 402 403 Hawaiians (MEC-NH). MEC-J and MEC-W subcohorts were used as benchmarks for the 404 prediction accuracies of PGS trained and optimized in East Asian and European populations, 405 respectively.

406 We removed population outliers for each population using the results from unsupervised 407 ADMIXTURE v1.3.0 [45] with the 1000 Genomes Project populations to guide the interpretation 408 of inferred ancestry components. We pruned the SNPs for linkage disequilibrium (LD) using the -409 -geno 0.05 and --indep-pairse 100 10 0.1 commands in PLINK v1.9[46]. For the ADMIXTURE 410 analysis, we set K=5, and each K was calculated for 5 repetitions. For MEC-J and MEC-W, we 411 removed individuals admixed within the last 1-2 generations and defined a relatively unadmixed 412 subset based on an inferred minimum of 95% genetic components of East Asian and European 413 ancestries, respectively. While fully recognizing that genetic ancestries exist on a continuum, and 414 any attempt to define a discrete population on the basis of inferred genetic ancestry will be arbitrary, 415 we opted to rely on inferred genetic ancestry to define our EAS and EUR populations in alignment 416 with the common practices in the field and with the ancestries of the source populations for the 417 GWAS data we used. In total, we retained 18,705 individuals in MEC-J (MEGA: 4,828; GDA: 418 13,877) and 8,532 individuals in MEC-W (MEGA: 634; GDA: 7,898) for analysis. We did not 419 filter out any self-reported Native Hawaiian individuals on the basis of estimated genetic ancestry, 420 since it is a well-known admixed population with a continuous cline of any major ancestry 421 components that can be estimated [15]. Furthermore, it is the community belief that estimated 422 genetic ancestries should not be used as an exclusion criterion for community membership and 423 should not supplant well-established custom of self-identity or genealogical records. Therefore, 424 we included all self-reported Native Hawaiians within the MEC as a single population, although 425 at times we do evaluate the efficacy of PGS models for subset of MEC-NH with higher proportion 426 of estimated Polynesian ancestry, both for a better evaluation of using PGS in realizing precision 427 medicine at the individual level and for assessment of the generalizability of PGS models to other 428 Polynesian-ancestry populations.

429 To avoid overfitting PGS models in validation cohort, we randomly subset the individuals 430 into three non-overlapping groups when evaluating PGS models for BMI and height: 500 431 individuals per population for LD reference, 3000 individuals per population for optimizing the 432 PGS model, and 1000 individuals per population for validating the PGS model (Fig. 1). For T2D, 433 we randomly selected 800 cases as well as 1500 controls for a total of 2300 individuals per 434 population for optimization. We then used all remaining cases and controls from each cohort for 435 validation: 3315 cases and 6700 controls for MEC-J, 496 cases and 4063 controls for MEC-W, 436 392 cases and 549 controls for MEC-NH. T2D cases were defined based on any self-reported T2D 437 diagnosis by a physician or medical professional, or the use of medication for treatment of diabetes, 438 on questionnaire 1 to 5 of the MEC survey or based on Medicare claim data based on ICD-9 codes 439 (249-250.99) or ICD-10 codes (E11.X [47,48]). using information from the phenotype file, 440 including patient age and T2D status. This process involves tracking individuals over time, 441 considering records across decades. If an individual's T2D status changes from negative to positive 442 in later traces, the record is updated accordingly. Our strategy entails evaluating all available

It is made available under a CC-BY-NC-ND 4.0 International license .

records for each person across five time points. Records with missing data are excluded, ensuring the reliability of our findings. For individuals used as LD reference or as validation, we randomly selected individuals who were genotyped on the MEGA array or GDA array, respectively, for each of MEC-J, MEC-W, and MEC-NH. For individuals used in optimizing PGS model, we selected from those genotyped on the MEGA array for MEC-J and MEC-NH and from those genotyped on the GDA array for MEC-W due to availability of samples.

449

450 **Polygenic Score development and validation**

451 Two commonly used approaches were utilized in this study to construct the PGS model: 452 Clumping and Thresholding (C+T) [6,49] and LDpred2 [7]. The C+T method involved clumping SNPs in LD based on r², and distance (kb) parameters, and thresholding SNPs based on specific 453 454 thresholds of p-values [50-52]. On the other hand, LDpred2 employed the Bayesian method to 455 estimate the effects of genetic variants on a specific trait and considered the LD information 456 between genetic variants [53]. We followed previous studies [54] in constructing PGS models from 457 C+T and LDpred2, with the following modifications. For the C+T, we used p-values thresholds 458 of: 0.1, 0.2, 0.5, 0.05, 0.01, 0.005, 1e-3, 5e-4, 1e-4, 5e-5, 1e-5, 5e-6, 1e-6, 5e-7, 1e-7, 5e-8; r2 459 values (based on the LD reference sample of 500 individuals) of: 0.2, 0.1, 0.01, 0.005, and distance in kilobases (kb) window sizes: 250, 500. Together we evaluated 128 combinations of parameters 460 461 to identify the optimal PGS (by partial R^2 and pseudo R^2 for quantitative and dichotomous traits, 462 respectively; see below) in the optimization sample of 3000 individuals. For LDpred2, we used a 463 grid of values for hyper-parameters/tuning parameter - causal variants (ρ), h^2 (the SNP heritability), 464 and sparsity (whether to fit some variant effects to exactly zero) to construct PGS. We used p from a sequence of 17 values from 0.01 to 1 on a log-scale, a range of h^2 within (0.7, 1, 1.4) × estimated 465 466 heritability, and a binary sparsity option of either on and off (LDPred2-grid models). In addition, 467 we tested a model assuming infinitesimal causal effects, where each variant assumed to contribute 468 to disease risk (LDPred2-inf model). In total, we evaluated 103 PRS models using LDPred2.

469 To evaluate the association of a PGS model in either the optimizing sample or validation 470 sampling, we evaluated a regression model using the PGS for each individual as the predictor 471 variable and the trait or disease as response variable using R (version 4.0.0) [55]. For BMI and 472 height, the trait was stratified by sex, and regressed against age and age². We extracted the residuals 473 from the model using the R package stats v3.6.2 [55] and the residuals() function, and inverse 474 normalized the residuals using the R package norm v1.0 [55] and the qnorm() function. Finally, we merged the results from males and females. For covariates, we additionally included ten 475 476 Principal Component Analysis (PCA) data to adjust for the impact due to ancestry and population 477 structure. For T2D, we used logistic regression, with covariates age, sex, and ten principal 478 components. The primary metric of PGS model efficacy is the partial R² for quantitative traits and 479 pseudo R^2 for dichotomous traits. Partial R^2 was calculated using the R package rsq v2.5 [56] and 480 its function rsq.partial(). Pseudo R² was calculated using the R package DescTools v0.99.43 [57] and its function PseudoR2(). To obtain the pseudo R^2 with only the PGS score effect in the 481 dichotomous trait, we calculate the difference in pseudo R² between the full model (including PGS) 482 483 and the partial model (without the PGS score). To obtain confidence interval for the partial or 484 pseudo R², we computed the standard error from 1000 bootstrap samples. Transferability of PGS 485 is evaluated based on differences of the partial or pseudo R² between two populations or between 486 two PGS models. Significance is calculated based on testing differences in mean of the partial or 487 pseudo R² distribution from the bootstrap samples.

It is made available under a CC-BY-NC-ND 4.0 International license .

489 **Data and code availability**

Genetic data utilized in this study will be available on dbGAP (accession number:
phs002183.v1.p1). GWAS summary statistics were downloaded from literature, see Table S3 for
reference. For the downloaded PGS models from the PGS catalog, see Table S4. We built a
package to incorporate the pipeline for training, optimizing, and validating the PGS models. The
package is publicly available on GitHub: https://github.com/imyingchulo/gprs.

495

496 Supporting information

497 Table S1. Parameters of the best genomic PGS models in Design I.

For each combination of complex trait, GWAS dataset, and optimization cohort, this table lists the model parameters and performance (in the optimization cohort) for the best genomic PGS model. To optimize, each combination of trait and GWAS was evaluated in a grid-like search in the optimization cohort, with the best performing model among the candidate 128 C+T models and 103 LDpred2 models. Across all combinations of GWAS dataset and traits, LDpred2 produced the best model based on partial R^2 (for BMI and height) or pseudo R^2 (for T2D) in the optimization

504 cohort in 11 out of 14 instances.

505

506 Table S2. Parameters of optimal genomic PGS models when optimized in MEC-NH (Design

507 **II).** As is the case for Table S1, but the optimization cohort is in MEC-NH in each case. 508

509 Table S3. Details of GWAS summary statistics and references used in this study.

510 This table provides the overview of GWAS datasets used in this study, including the data resources, 511 cohort, SNPs, genome built, and population size.

512

513 Table S4. Additional information of PGS models from PGS catalog evaluated in this study

514 This table provides the references and additional information for the 39 PGS models included in 515 this study.

516

517 Acknowledgments

518 We would like to thank David Conti and Hailiang Huang for discussions of the analysis and 519 release of pre-publication summary statistics. We would also like to thank the Native Hawaiian 520 participants in the Multiethnic Cohort that are involved in this study. The Multiethnic Cohort was funded through grants from the National Cancer Institute (U01CA164973, P01CA168530) and 521 522 National Human Genome Research Institute (U01HG007397). We also would like to thank 523 University of Hawai'i Cancer Center's Native Hawaiian Community Advisory Board for 524 reviewing the study proposal and providing comments to earlier versions of this manuscript. This 525 study is supported by grants from the National Human Genome Research Institute (R01HG011646 526 to C.W.K.C.) and the Taiwan-USC Postdoctoral Fellowship from Taiwan Education Ministry. 527 Computation for this work was supported by the University of Southern California's Center for 528 High-Performance Computing (https://hpcc.usc.edu).

- 529
- 530
- 531
- 532
- 533
- 534

It is made available under a CC-BY-NC-ND 4.0 International license .

535 References

- Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genomewide association studies. Nat Rev Genet. 2019;20: 467–484. doi:10.1038/s41576-019-0127-1
- Uffelmann E, Huang QQ, Munung NS, de Vries J, Okada Y, Martin AR, et al. Genome-wide
 association studies. Nature Reviews Methods Primers. 2021;1: 59. doi:10.1038/s43586-021 00056-9
- Igo RPJ, Kinzy TG, Cooke Bailey JN. Genetic Risk Scores. Curr Protoc Hum Genet.
 2019;104: e95. doi:10.1002/cphg.95
- Goldstein BA, Yang L, Salfati E, Assimes TL. Contemporary Considerations for
 Constructing a Genetic Risk Score: An Empirical Approach. Genetic Epidemiology.
 2015;39: 439–445. doi:10.1002/gepi.21912
- 546 5. Pain O, Glanville KP, Hagenaars SP, Selzam S, Fürtjes AE, Gaspar HA, et al. Evaluation of
 polygenic prediction methodology within a reference-standardized framework. PLoS Genet.
 2021;17: e1009021. doi:10.1371/journal.pgen.1009021
- 6. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15: 2759–2772. doi:10.1038/s41596-020-0353-1
- Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinformatics.
 2021;36: 5424–5431. doi:10.1093/bioinformatics/btaa1029
- 553 8. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments.
 554 Genome Medicine. 2020;12: 44. doi:10.1186/s13073-020-00742-5
- 555 9. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk
 556 scores. Nature Reviews Genetics. 2018;19: 581–590. doi:10.1038/s41576-018-0018-x
- 557 10. Fullerton A.B. & Popejoy S.M. Genomics is failing on diversity. Nature. 2016; 161–164.
- 11. Peterson RE, Kuchenbaecker K, Walters RK, Chen C-Y, Popejoy AB, Periyasamy S, et al.
 Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities,
 Methods, Pitfalls, and Recommendations. Cell. 2019;179: 589–603.
 doi:10.1016/j.cell.2019.08.051
- 562 12. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic
 563 risk score usage and performance in diverse human populations. Nature Communications.
 564 2019;10: 3328. doi:10.1038/s41467-019-11112-0
- Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current
 polygenic risk scores may exacerbate health disparities. Nature Genetics. 2019;51: 584–591.
 doi:10.1038/s41588-019-0379-x

It is made available under a CC-BY-NC-ND 4.0 International license .

- 568 14. Detailed Look at Native Hawaiian and Other Pacific Islander Groups. [cited 30 Nov 2023].
 569 Available: https://www.census.gov/library/stories/2023/09/2020-census-dhc-a-nhpi 570 population.html
- 571 15. Sun H, Lin M, Russell EM, Minster RL, Chan TF, Dinh BL, et al. The impact of global and
 572 local Polynesian genetic ancestry on complex traits in Native Hawaiians. PLOS Genetics.
 573 2021;17: e1009273. doi:10.1371/journal.pgen.1009273
- 16. Moy KL, Sallis JF, Trinidad DR, Ice CL, McEligot AJ. Health behaviors of native Hawaiian
 and Pacific Islander adults in California. Asia Pac J Public Health. 2012;24: 961–969.
 doi:10.1177/1010539511408068
- 577 17. Galinsky AM, Zelaya CE, Simile C, Barnes PM. Health Conditions and Behaviors of Native
 578 Hawaiian and Pacific Islander Persons in the United States, 2014. Vital Health Stat 3. 2017;
 579 1–99.
- 18. Aluli NE, Jones KL, Reyes PW, Brady SK, Tsark JU, Howard BV. Diabetes and
 cardiovascular risk factors in Native Hawaiians. Hawaii Med J. 2009;68: 152–157.
- 19. Madan A, Archambeau OG, Milsom VA, Goldman RL, Borckardt JJ, Grubaugh AL, et al.
 More than black and white: differences in predictors of obesity among Native
 Hawaiian/Pacific Islanders and European Americans. Obesity (Silver Spring, Md). 2012;20:
 1325–1328. doi:10.1038/oby.2012.15
- 586 20. Native Hawaiian/Other Pacific Islander The Office of Minority Health. [cited 4 Aug 2023].
 587 Available: https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=65
- 588 21. Haque AT, Berrington de González A, Chen Y, Haozous EA, Inoue-Choi M, Lawrence WR,
 589 et al. Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020. J
 590 Natl Cancer Inst. 2023;115: 822–830. doi:10.1093/jnci/djad069
- 591 22. Taparra K, Qu V, Pollom E. Disparities in Survival and Comorbidity Burden Between Asian
 592 and Native Hawaiian and Other Pacific Islander Patients With Cancer. JAMA Netw Open.
 593 2022;5: e2226327. doi:10.1001/jamanetworkopen.2022.26327
- 594 23. Chiang CWK. The Opportunities and Challenges of Integrating Population Histories Into
 595 Genetic Studies for Diverse Populations: A Motivating Example From Native Hawaiians.
 596 Frontiers in Genetics. 2021;12. doi:10.3389/fgene.2021.643883
- 597 24. Taparra K, Miller RC, Deville CJ. Navigating Native Hawaiian and Pacific Islander Cancer
 598 Disparities From a Cultural and Historical Perspective. JCO Oncol Pract. 2021;17: 130–134.
 599 doi:10.1200/OP.20.00831
- 25. Taparra K. Pacific Islanders Searching for Inclusion in Medicine. JAMA Health Forum.
 2021;2: e210153. doi:10.1001/jamahealthforum.2021.0153

It is made available under a CC-BY-NC-ND 4.0 International license .

602	 Lin M, Caberto C, Wan P, Li Y, Lum-Jones A, Tiirikainen M, et al. Population-specific
603	reference panels are crucial for genetic analyses: an example of the CREBRF locus in Native
604	Hawaiians. Human Molecular Genetics. 2020;29: 2275–2284. doi:10.1093/hmg/ddaa083
605	 Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A
606	multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol.
607	2000;151: 346–357. doi:10.1093/oxfordjournals.aje.a010213
608	 Aluli NE. Prevalence of obesity in a Native Hawaiian population. The American Journal of
609	Clinical Nutrition. 1991;53: 1556S-1560S. doi:10.1093/ajcn/53.6.1556S
610 611 612	29. Maskarinec G, Grandinetti A, Matsuura G, Sharma S, Mau M, Henderson BE, et al. Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort. Ethn Dis. 2009;19: 49–55.
613	 Galinsky AM, Zelaya CE, Barnes PM, Simile C. Selected Health Conditions Among Native
614	Hawaiian and Pacific Islander Adults: United States, 2014. NCHS Data Brief. 2017; 1–8.
615	 Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, et al. The Polygenic Score
616	Catalog as an open database for reproducibility and systematic evaluation. Nature Genetics.
617	2021;53: 420–425. doi:10.1038/s41588-021-00783-5
618 619 620	32. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics. 2022;54: 560–572. doi:10.1038/s41588-022-01058-3
621	 Ding Y, Hou K, Xu Z, Pimplaskar A, Petter E, Boulier K, et al. Polygenic scoring accuracy
622	varies across the genetic ancestry continuum. Nature. 2023;618: 774–781.
623	doi:10.1038/s41586-023-06079-4
624	34. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-
625	population atlas of genetic associations for 220 human phenotypes. Nature Genetics.
626	2021;53: 1415–1424. doi:10.1038/s41588-021-00931-x
627 628 629 630	35. Privé F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. The American Journal of Human Genetics. 2022;109: 12–23. doi:10.1016/j.ajhg.2021.11.008
631	36. Hudson M, Garrison NA, Sterling R, Caron NR, Fox K, Yracheta J, et al. Rights, interests
632	and expectations: Indigenous perspectives on unrestricted access to genomic data. Nature
633	Reviews Genetics. 2020;21: 377–384. doi:10.1038/s41576-020-0228-x
634	37. Kwan P, Briand G, Lee C, Lepule J, Llave K, Pang K, et al. Reservations to Participate in
635	Biospecimen Research among Pacific Islanders. Calif J Health Promot. 2015;13: 27–33.


It is made available under a CC-BY-NC-ND 4.0 International license .

636	 Garrison NA, Hudson M, Ballantyne LL, Garba I, Martinez A, Taualii M, et al. Genomic
637	Research Through an Indigenous Lens: Understanding the Expectations. Annu Rev
638	Genomics Hum Genet. 2019;20: 495–517. doi:10.1146/annurev-genom-083118-015434
639	 Mau MK, Sinclair K, Saito EP, Baumhofer KN, Kaholokula JK. Cardiometabolic health
640	disparities in native Hawaiians and other Pacific Islanders. Epidemiol Rev. 2009;31: 113–
641	129. doi:10.1093/ajerev/mxp004
642	 Akiyama M, Okada Y, Kanai M, Takahashi A, Momozawa Y, Ikeda M, et al. Genome-wide
643	association study identifies 112 new loci for body mass index in the Japanese population.
644	Nature Genetics. 2017;49: 1458–1467. doi:10.1038/ng.3951
645	41. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis
646	of genome-wide association studies for height and body mass index in ~700000 individuals
647	of European ancestry. Hum Mol Genet. 2018;27: 3641–3649. doi:10.1093/hmg/ddy271
648	42. Akiyama M, Ishigaki K, Sakaue S, Momozawa Y, Horikoshi M, Hirata M, et al.
649	Characterizing rare and low-frequency height-associated variants in the Japanese population.
650	Nature Communications. 2019;10: 4393. doi:10.1038/s41467-019-12276-5
651 652 653 654	43. Chia-Yen Chen, Tzu-Ting Chen, Yen-Chen Anne Feng, Ryan J. Longchamps, Shu-Chin Lin, Shi-Heng Wang, et al. Analysis across Taiwan Biobank, Biobank Japan and UK Biobank identifies hundreds of novel loci for 36 quantitative traits. medRxiv. 2021; 2021.04.12.21255236. doi:10.1101/2021.04.12.21255236
655 656 657 658	44. Sheng X, Xia L, Cahoon JL, Conti DV, Haiman CA, Kachuri L, et al. Inverted genomic regions between reference genome builds in humans impact imputation accuracy and decrease the power of association testing. HGG Adv. 2023;4: 100159. doi:10.1016/j.xhgg.2022.100159
659	 Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated
660	individuals. Genome Res. 2009;19: 1655–1664. doi:10.1101/gr.094052.109
661	46. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a
662	tool set for whole-genome association and population-based linkage analyses. Am J Hum
663	Genet. 2007;81: 559–575. doi:10.1086/519795
664 665 666	47. Polfus LM, Darst BF, Highland H, Sheng X, Ng MCY, Below JE, et al. Genetic discovery and risk characterization in type 2 diabetes across diverse populations. HGG Adv. 2021;2: 100029. doi:10.1016/j.xhgg.2021.100029
667	48. Maskarinec G, Brown SM, Lee J, Bogumil D, Walsh C, Haiman CA, et al. Association of
668	Obesity and Type 2 Diabetes with Non-Hodgkin Lymphoma: The Multiethnic Cohort.
669	Cancer Epidemiol Biomarkers Prev. 2023; EPI-23-0565. doi:10.1158/1055-9965.EPI-23-
670	0565


It is made available under a CC-BY-NC-ND 4.0 International license .


- 671 49. Collister JA, Liu X, Clifton L. Calculating Polygenic Risk Scores (PRS) in UK Biobank: A
 672 Practical Guide for Epidemiologists. Front Genet. 2022;13: 818574.
 673 dai:10.2280/facera.2022.818574.
- 673 doi:10.3389/fgene.2022.818574
- 50. Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh P-R, et al. Partitioning
 heritability by functional annotation using genome-wide association summary statistics.
 Nature Genetics. 2015;47: 1228–1235. doi:10.1038/ng.3404
- 51. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM, et al.
 Genome partitioning of genetic variation for complex traits using common SNPs. Nature
 Genetics. 2011;43: 519–525. doi:10.1038/ng.823
- 52. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian
 regression and continuous shrinkage priors. Nature Communications. 2019;10: 1776.
 doi:10.1038/s41467-019-09718-5
- 53. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, et al. Modeling
 Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. The American
 Journal of Human Genetics. 2015;97: 576–592. doi:10.1016/j.ajhg.2015.09.001
- 54. Jeon S, Lo YC, Morimoto LM, Metayer C, Ma X, Wiemels JL, et al. Evaluating genomic
 polygenic risk scores for childhood acute lymphoblastic leukemia in Latinos. Human
 Genetics and Genomics Advances. 2023;4: 100239. doi:10.1016/j.xhgg.2023.100239
- 55. R Core Team. R: A language and environment for statistical computing. R Foundation for
 Statistical Computing, Vienna, Austria. 2023.
- 56. Zhang D. rsq: R-Squared and Related Measures. 2022. Available: https://cran.r project.org/web/packages/rsq/index.html
- 57. Signorell A, Aho K, Alfons A, Anderegg N, Aragon T, Arachchige C, et al. DescTools:
 Tools for Descriptive Statistics. 2023. Available: https://cran.rproject.org/web/packages/DescTools/index.html

696




Design II: optimized PGS in Native Hawaiians






BMI validated in MEC-NH




HEIGHT validated in MEC-NH



LDpred2 – PGS opt	timized in this study
-------------------	-----------------------

- C+T PGS optimized in this study
- PGS downloaded from the PGS catalog



_0.003	0.001	0.010	_0.007	0.014
PGS000805	PGS000807	PGS001357	PGS001818	PGS002243

BMI PGS validated in MEC-NH

